Figure 2
(a) Colony formation in primary AML cells is inhibited by mevastatin in the presence or absence of ubiquinone. Bone marrow cells from patients with AML were cultured in colony forming assays with growth factors in control conditions (DMSO alone), mevastatin (MST, 30 M + DMSO), ubiquinone (Ubi, 5 M), or mevastatin + ubiquinone (MST + Ubi). Patients A, B and C were newly diagnosed and untreated AML patients with 51 to 85% blasts in their bone marrows. Patient D had MDS with excess blasts (6%). Samples were obtained with written informed consent from patients undergoing bone marrow biopsies for clinical purposes under protocols approved by the Committee for Protection of Human Subjects. Cells obtained after ammonium chloride lysis (Stem Cell Technologies, SCT, Vancouver, BC, Canada, catalog No. 07850) were plated in methylcellulose media with recombinant growth factors (SCT, Methocult GF, catalog No. H4434). The number of myeloid colonies present on day 16 of culture in untreated cultures was compared to the number of colonies formed in the presence of mevastatin (30 M), with or without ubiquinone at physiological concentrations (5 M). Mevastatin decreased colony formation and ubiquinone did not rescue cells from this effect. (b) Mevastatin decreases membrane localization of Ras and this is not affected by ubiquinone. Cells were cultured in the presence or absence of 50 M mevastatin ±50 M ubiquinone (Ubi). Prenylated Ras was assayed by fractionating cell lysates into lipophilic (membrane, MB) and aqueous (cytosol, CS) components using Triton X114. The samples were separated by SDS gel electrophoresis and immunoblotted using a pan-Ras antibody. Mevastatin inhibited prenylation of Ras in both K562 cells and in MEL cells. This effect was not abrogated by ubiquinone.
Inhibition affecting RQ-PCR-based assessment of minimal residual disease in acute lymphoblastic leukemia: reversal by addition of bovine serum albumin Leukemia (2003) Ubiquinone did not rescue AML cells from statin-induced in vitro alterations on cellular proliferation, colony formation, or prenylation suggesting that ubiquinone will not abrogate the potential therapeutic effects of statins in AML. Ubiquinone may allow some patients to tolerate the relatively high doses of statins that may be required to treat AML. Appropriately designed clinical trials will be needed to address the potential utility of statins, with or without ubiquinone, in the treatment of patients with AML.
method for the detection of minimal residual disease (MRD) in the bone marrow (BM) or peripheral blood (PB) of children with acute lymphoblastic leukemia (ALL). The main advantages of RQ-PCR over other methodologies for the detection of MRD are its ability to reproducibly and sensitively quantify the level of MRD. Accuracy of this quantification is entirely dependent upon knowledge of the quantity and amplifiability of target DNA. The amount of DNA added is initially assessed by spectrophotometry, and subsequently checked by use of a suitable control PCR, which also assesses the quality (amplifiability) of the DNA. In the European pre-BMT MRD consortium and I-BFM-SG MRD Task Force, 500 ng of target DNA is subjected to an albumin gene control RQ-PCR. In the majority of samples, the albumin gene RQ-PCR indicates that amplifiable DNA is present within an acceptable experimental range (250-1000 ng). However, upon examination of 316 samples from 15 patients, we found that the albumin RQ-PCR gave discrepant quantification compared to spectrophotometry (RQ-PCR value Ͻ50% of that suggested by spectrophotometry) in 18% of samples. Agarose gel-based analysis of DNA integrity in these samples confirmed that the DNA was not degraded. Therefore, the most likely explanation for this phenomenon was the presence of PCR inhibitors. As such inhibitors may hamper quantitative MRD analysis, we investigated this in more detail.
Cell samples (BM and/or PB) were obtained from patients with ALL at diagnosis and during follow-up, and DNA was isolated as described previously.
1 RQ-PCR analysis of the albumin control gene and Ig/TCR gene rearrangements (IGH, IGK-Kde, TCRD and TCRG) was performed as described. 2, 3 For control PCR quantification, a standard curve was generated by logarithmic dilution of normal DNA (obtained from MNC of eight pooled normal blood donations) into water. 2, 3 For MRD target PCRs a standard curve was generated by logarithmic dilution of diagnostic DNA into normal DNA. 2, 3 Fourteen samples in which spectrophotometry and albumin control RQ-PCR gave discrepant results were diluted 10-fold in water and retested in duplicate in the albumin control RQ-PCR (Figure 1a ). This resulted in a median 36-fold improvement in the amplifiability (range: 6-112 000-fold). This strongly suggested the presence of soluble PCR inhibitors that are rendered less effective by the dilution of the sample. We next investigated whether this inhibition was particularly seen in the albumin control RQ-PCR. To this end, 21 samples were tested in either TCR-C␣ (constant gene segment TCRA) or ␤ 2 microglobulin (B2M) control RQ-PCRs. The results (data not shown) confirmed that both alternative control RQ-PCRs improved similarly to the albumin control RQ-PCR when analyzed at 10-fold dilution. However, the magnitude of inhibition differed per RQ-PCR, the albumin RQ-PCR being the most sensitive to inhibitors.
To investigate whether this inhibition was reversible, 20 samples with discrepant RQ-PCR results were re-tested in the presence of bovine serum albumin (BSA, Sigma-Aldrich, Poole, UK). The final BSA concentration was 0.2% for samples A-F and 0.04% for samples G- 
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T. All but one of these samples (sample A) showed considerable improvement in the quantity of amplifiable DNA detected when BSA was added (Table 1 ). An example of albumin RQ-PCR results in the presence or absence of BSA is shown in Figure 1c . By contrast, the addition of BSA to samples in which spectrophotometric and RQ-PCRbased quantification agreed did not alter the results of RQ-PCR based analysis (data not shown). Similarly, the addition of BSA to the samples used to form the standard curves against which quantification is assessed did not alter the standard curves obtained. Thus, BSA does not seem to be acting as a simple PCR facilitator, where the amplification of every sample is improved. Rather it preferentially improves the amplification of inhibited samples.
Two of the samples giving discrepant RQ-PCR-based control results, which had shown 179% and 191% improvement in the albumin RQ-PCR when diluted 10-fold, had detectable levels of MRD as determined by use of a clone-specific IGH RQ-PCR. The levels of MRD detected in these samples (1.9 × 10 −3 and 1.2 × 10 −3
) showed, however, no change when a similar 10-fold dilution was made (Figure 1b) . Apparently, the clone-specific IGH RQ-PCR did not seem to show the same degree of inhibition as the albumin RQ-PCR.
However, improvements in amplification were seen in Ig/TCR RQPCRs designed to quantify MRD when BSA was added ( Table 1) . Addition of BSA to samples B, E, H, J and M improved the level of MRD markedly (Figure 1d ). On other occasions, despite improving quantification in control PCRs, the addition of BSA did not improve the level of MRD detected (samples G, I and N). In two cases (K and L), addition of BSA did not improve either the albumin RQ-PCR or the clone-specific RQ-PCR. Overall, it appears that levels of inhibition vary between control PCR and target PCR performed on the same sample.
As these experiments had been performed using two different concentrations of BSA, further experiments were performed to determine the concentration of BSA required to maximally reverse the inhibition of samples. Serial dilutions of BSA were made and the minimum concentration at which maximal reversal of inhibition could be obtained was assessed. These experiments showed that maximal reversal was consistently achieved by a final concentration of 0.01% BSA and that a final concentration in the RQ-PCR of up to 1% BSA (maximum tested) had no deleterious effect upon RQ-PCR efficiency (as determined by ⌬Rn and Ct of standard samples). Concentrations above 1% are difficult to achieve due to the increasingly viscous nature of BSA above concentrations of 10%, and were not tested. Finally, attempts were made to determine whether heparin contamination was responsible for the inhibition seen. To this end, samples that had previously shown significant inhibition were pre-incubated with 0.5 IU heparinase II (Sigma-Aldrich) for 30 min, with or without additional BSA. These experiments showed that heparinase II has an equivalent, but not additive effect to that achieved by BSA. However, as all available commercial heparinases are provided suspended in BSA, an effect of BSA cannot be excluded.
In conclusion, a minority of DNA samples (~15%) obtained from bone marrow and processed in accordance with European standard guidelines, contain inhibitors which adversely affect both the DNA quantification and the assessment of MRD levels. Known PCR inhibitors that may be responsible include hemoglobin, lactoferrin, immunoglobulin and heparin. [4] [5] [6] The addition of BSA can overcome this inhibition and has no deleterious effects upon either standard curves or DNA samples without signs of inhibition. Our results show that the routine addition of BSA to TaqMan-based RQ-PCR analysis helps to avoid the possibility that clinically relevant levels of MRD are missed. It should be noted that BSA is added routinely to samples analyzed using LightCycler technology. For detection of MRD in ALL, we suggest that a final concentration of 0.04% BSA be added routinely to all TaqMan-based RQ-PCR reactions. 
